Sutro Biopharma is covered by a broad but unusually divergent set of sell-side analysts. The average analyst price target of roughly $50 is the mean of about nine identifiable, current targets spanning from approximately $34 to $60. The dispersion is telling: Wedbush set a $60 target in October 2026, while H.C. Wainwright reiterated a $50 target and Wells Fargo a $49 target. Barclays initiated coverage with a $56 target, Stifel and Truist set targets around $48–$50, LifeSci Capital at $54, and Citizens (JMP) lowered its target to $34. Mizuho initiated at $50.
That range reflects a fundamental disagreement about how much value remains after Sutro's strategic reset. In early October 2026 the company deprioritized its lead ADC, luveltamab tazevibulin (luvelta, STRO-002), across all indications, cut roughly half its workforce, and installed Jane Chung as chief executive. Bullish targets lean on the wholly owned next-generation pipeline, while the lower targets reflect reduced revenue assumptions and the loss of the lead program's near-term value. Because some targets may still embed pre-restructuring assumptions, the calculated mean should be read as a reference point rather than an official consensus.
At about $9.10, STRO trades near the low end of its 52-week range of roughly $7.15 to $43.85, with a market capitalization of approximately $151 million. Reaching $50 would require a gain of roughly 450%, a very large move that would revalue the company toward the $800 million-to-$1 billion range implied by the higher targets.
The path hinges almost entirely on clinical data. Sutro's future now centers on STRO-004, a tissue-factor ADC in Phase 1 dose optimization, plus STRO-006, which dosed its first patient in October 2026, and STRO-227, a dual-payload ADC targeting PTK7 with an IND (investigational new drug) submission planned for 2026. Unlike a profitable company that can compound toward a price forecast through earnings, this stock forecast depends on early efficacy and safety readouts, partnerships, and financing decisions.
Sutro's cell-free XpressCF and XpressCF+ platforms allow site-specific ADC construction, and its collaborations with Astellas, Vaxcyte, and Ipsen provide both validation and potential milestone payments. The company reported $164.3 million in cash as of June 30, 2026, supporting operations into at least the second quarter of 2028, which reduces near-term dilution risk. Encouraging early STRO-004 data—including partial responses across pancreatic, head and neck, and lung cancers—gives analysts a basis for the bullish side of the target range. A positive STRO-004 update, a new partnership, or a revaluation of the ADC platform could meaningfully lift the market outlook.
The risks are substantial. Deprioritizing luvelta removed the company's most advanced clinical asset, and the workforce reduction and CEO change introduce execution risk across the remaining pipeline. STRO-004, STRO-006, and STRO-227 are all early-stage, and oncology programs frequently fail to replicate early signals. Revenue is declining: second-quarter 2026 revenue was $9.8 million versus $63.7 million a year earlier, and the company reported a net loss of $38.5 million. As an unprofitable micro-cap, the stock remains vulnerable to dilution, clinical setbacks, and sector-wide risk-off moves that could keep the share price far below any analyst price target.
The $7.15 52-week low acts as a key support level, while the stock's slide from its $43.85 high leaves a broken long-term structure. Near-term resistance appears in the $11–$12 zone, where the shares have struggled after the post-restructuring decline. A sustained recovery would first require reclaiming those levels before any meaningful move toward the $34 low end of the target range becomes relevant.
Analyst price targets typically reflect a roughly 12-month research horizon, though the exact horizon varies by firm. For Sutro, the relevant catalysts are clinical rather than calendar-driven: the next STRO-004 STRIVE-01 update (targeted for the first half of 2027), STRO-006 dose-escalation progress, STRO-227's IND submission, and any partnership or financing announcements. Quarterly earnings—including the next report due in early November 2026—matter mainly for cash burn and runway commentary. Investors should also watch analyst revisions, which have been frequent and materially divergent.
For traders tracking volatile names like Sutro Biopharma, Tickeron's AI Daily Buy/Sell Signals offer an automated way to stay oriented. The system uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. It is designed to help traders discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual chart review allows. Consider using it to complement your own research on STRO and other holdings.
The question of whether Sutro Biopharma can reach $50 is ultimately a question about whether its next-generation ADC pipeline can recreate the value that luvelta was expected to deliver. The central target of $50, derived from the mean of current analyst targets, sits far above the roughly $9.10 market price and implies a roughly 450% move. Support comes from platform technology, partnerships, and a solid cash runway; the obstacles are a deprioritized lead asset, early-stage clinical risk, and a post-restructuring execution gap. With analyst targets ranging from $34 to $60, the wide dispersion itself signals deep uncertainty. Investors should treat the target as a multi-year, data-dependent scenario rather than a near-term expectation, and focus next on STRO-004 and STRO-006 clinical updates and any partnering activity.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, STRO has been loosely correlated with EDIT. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if STRO jumps, then EDIT could also see price increases.
| Ticker / NAME | Correlation To STRO | 1D Price Change % | ||
|---|---|---|---|---|
| STRO | 100% | +0.88% | ||
| EDIT - STRO | 43% Loosely correlated | -4.99% | ||
| NTLA - STRO | 42% Loosely correlated | +2.15% | ||
| TSHA - STRO | 41% Loosely correlated | +0.12% | ||
| CADL - STRO | 41% Loosely correlated | -1.39% | ||
| KYTX - STRO | 39% Loosely correlated | +0.79% | ||
More | ||||